Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has granted inducement awards to nine new employees under its Amended and Restated 2014 Inducement Plan. The awards, approved by the People & Compensation Committee on September 3, 2025, include:

• Stock Options: Six employees received options to purchase 13,000 shares at $27.18 per share, with a 10-year term and four-year vesting schedule
• Restricted Stock Units (RSUs): Nine employees received 18,100 RSUs, vesting annually in four equal installments starting September 1, 2026

BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Six employees received stock options to purchase an aggregate of 13,000 shares of Pacira common stock and nine employees received restricted stock units for an aggregate of 18,100 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $27.18 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on September 1, 2026.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera_®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com

FAQ

What inducement awards did Pacira BioSciences (PCRX) grant to new employees in September 2025?

Pacira granted 13,000 stock options to six employees and 18,100 restricted stock units to nine employees, with specific vesting schedules starting September 2026.

What is the exercise price for PCRX's newly granted stock options in September 2025?

The stock options were granted with an exercise price of $27.18 per share, which was Pacira's closing price on the Nasdaq Global Select Market on the grant date.

How do the vesting schedules work for Pacira's September 2025 inducement awards?

Stock options vest over 4 years with 25% vesting after year 1 and quarterly installments over 36 months thereafter. RSUs vest annually in four equal installments starting September 1, 2026.

Why did Pacira BioSciences issue these inducement awards?

The awards were granted as a material inducement for new employees joining the company, approved under Nasdaq Listing Rule 5635(c)(4) by the People & Compensation Committee.